Teleflex Gets FDA Clearance For ARROW JACC With Chlorag+ard Tech And Tunneler

(RTTNews) - Teleflex Inc. (TFX), a provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its Arrow® JACC with Chlorag+ard Technology and TightTrack tunneler.

Arrow JACC with Chlorag+ard Technology is a long-term, tunneled, small french size antithrombogenic and antimicrobial central venous catheter designed to meet the needs of patients throughout their course of therapy or illness. The catheter is also designed for use with high-pressure injection for diagnostic studies. The Arrow JACC with Chlorag+ard Technology protects against catheter occlusion, phlebitis, and intimal hyperplasia4 for up to 30 days. The Arrow JACC with Chlorag+ard Technology will enable caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients.